Brief: Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma

Valerio Therapeutics SA

11/09/2017 19:01

Sept 11 (Reuters) - Onxeo Sa  C4X.PA  -  
    * Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced 
hepatocellular carcinoma 
    * Study did not meet its primary endpoint of improving survival over the comparative group 
    * Monitoring of patients still enrolled in study will continue to completion expected in h1 
2019 
 
Source text for Eikon:  ID:nBw5nF2xwa  
Further company coverage:  C4X.PA  
 
 (Bengaluru Newsroom) 
 ((+1 646 223 8780;))